Posted by Michael Wonder on 24 Nov 2023
Handok's Vyxeos, Gilead's Trodelvy pass cancer drug review for insurance coverage
23 November 2023 - Handok’s Vyxeos liposomal Injection, a combination of cytarabine and daunorubicin for therapy-related acute myeloid leukaemia and acute myeloid leukaemia with myelodysplasia-related change, has crossed the first threshold for reimbursement in its second attempt.
Gilead Sciences’ Trodelvy (sacituzumab govitecan), a treatment for unresectable locally advanced or metastatic triple negative breast cancer, was successful in establishing a reimbursement standard at its first attempt.
